.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In May 2026, Breez concentrated 86.48% of sales in Capsules, where category sales fell 45.52% year over year and 2.21% month over month, while Edible held 7.48% share with a 23.74% YoY decline but a 10.15% MoM increase. Tincture & Sublingual represented 4.33% share with a 38.42% YoY decline and a 5.73% MoM lift, and Vapor Pens at 1.72% share contracted 70.02% YoY and 13.41% MoM. With overall brand sales down 44.84% YoY against a 4.08% YoY rise in average price, the mix indicates dependence on a shrinking Capsules base offset partly by MoM stabilization in smaller formats, implying near-term volume risk concentrated in a single category.
Holding rank 1 in Capsules in California positions Breez as the category anchor, but the 45.52% YoY and 2.21% MoM contractions in Capsules, alongside a 4.08% YoY increase in average price, point to a trade-off where price and leadership are not preventing volume erosion. The 10.15% MoM growth in Edible and 5.73% MoM growth in Tincture & Sublingual, despite 23.74% and 38.42% YoY declines respectively, signal early diversification levers; together with a 70.02% YoY and 13.41% MoM slide in Vapor Pens, the pattern implies Breez’s defensible position rests on Capsules strength in California while near-term share resilience will depend on accelerating Edible and Tincture & Sublingual to reduce exposure to a single category.
Competitive Landscape
Breez sits at rank #1 in CA Capsules in May 2026 after rising 1 position year over year from #2, and it has held #1 for the past three months while reaching its peak rank in May 2026; against this, Level slipped from #1 to #2 as its sales fell 67.8% year over year, and ABX / AbsoluteXtracts remains #3 with a 40.0% YoY sales decline, indicating Breez’s ascent is occurring while adjacent leaders contract. Further down the leaderboard, Buddies climbed from #6 to #4 despite an 18.6% YoY sales decrease and Kikoko slipped from #4 to #5 with a 39.8% YoY drop, which suggests Breez’s upward rank trajectory stems more from relative outperformance amid category retrenchment than from broad market expansion.
Notable Products
CBD Extra Strength Recovery Tablet 50-Pack (1000mg CBD) posted the steepest decline in May 2026 at -20.3% and sat at rank 7, while CBD/THC/CBN 2:1:1 Nighttime Extra Strength Tablets 50-Pack (500mg CBD, 250mg THC, 250mg CBN) fell -15.5% to rank 8. In contrast, Sativa Extra Strength Tablet 50-Pack (1000mg) rose +10.7% at rank 2 and Original Mint Tin 20-Pack (100mg) advanced +14.7% at rank 4, with Indica Royal Mint 10-Pack (100mg) sliding -11.9% at rank 10. Four of the top ten are Capsules, but Edible mints at ranks 4–6 grew between +14.7% and +35.3% while three CBD-heavy Capsules at ranks 7–9 contracted between -10.7% and -20.3%, implying a shift from wellness-oriented CBD formats toward faster-turning mints despite the Capsules franchise still anchoring the top three by rank.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
